Today's Top SOA Links
From the Wires
PharmaForm announces job fair to be held Saturday November 10th in La Jolla-San Diego, California
By: PR Newswire
Nov. 6, 2012 12:25 PM
SAN DIEGO, CA, Nov. 6, 2012 /PRNewswire/ - PharmaForm, a leader in pharmaceutical dosage formulation, development, and GMP manufacturing today announced a recruiting job fair to be held Saturday, November 10, 2012 from 9am to 3pm at the Embassy Suites Hotel located at 4550 La Jolla Village Drive, San Diego CA.
PharmaForm is holding open interviews on Saturday November 10th with callbacks and scheduled interviews on Sunday November 11th. Open positions include: PhD Senior Scientists/Group Leaders (in Formulations, Manufacturing & Analytical); Pharmaceutical Formulators; Pharma Manufacturing Manager; Pharma GMP Manufacturing Operators; Manager Analytical Chemistry; Analytical Chemists; Qualification Engineer; Lab Technicians; Warehouse Coordinator; Technical Batch Records Writer; Equipment Maintenance Specialists; QA Manager; QA Specialists; Senior Staff and Staff Accountant; Accounting Clerks; and a Receptionist/Executive Administrator.
Responsibilities and minimum requirements can be viewed at http://www.pharmaform.com/pages/careers
For a scheduled appointment consideration, please send your CV or Resume to firstname.lastname@example.org by Wednesday November 7, 2012.
PharmaForm is a leading specialty contract manufacturer in the area of pharmaceutical dosage form development, specializing in controlled release and bioavailability enhancement technologies, such as hot melt extrusion, liquid filled capsules, and spray drying. PharmaForm remains an industry leader in the formulation of potent compounds and controlled release drug delivery. Working with solid oral dosage (tablets, capsules and film coating) as well as HME novel dosage forms (oral dissolving thin films, transmucosal and oral tablets & Capsules) and creams, emulsions, gels, nasal spray and dry powder inhalation.
This press release contains statements which may constitute forward-looking information under applicable Canadian securities legislation or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1955. Such forward-looking statements or information may include financial and other projections as well as statements regarding the company's future plans, objectives, performance, revenues, growth, profits, operating expenses or the company's underlying assumptions. The words "may", "would", "could", "will", "likely", "expect", anticipate", "intend", "plan", "forecast", "project", "estimate" and "believe" or other similar words and phrases may identify forward-looking statements or information. Persons reading this press release are cautioned that such statements or information are only expectations, and that the company's actual future results or performance may be materially different.
Forward-looking statements or information in this press release include, but are not limited to, statements or information concerning our ongoing drug development programs and collaborations as well as the possible receipt of future payments upon achievement of milestones.
Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments to be materially different from results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, the possibility that risks associated with requirements for approvals by government agencies such as the FDA before products can be tested in clinical trials; the possibility that such government agency approvals will not be obtained in a timely manner or at all or will be conditioned in a manner that would impair our ability to advance development; risks associated with the requirement that a drug candidate be found safe and effective after extensive clinical trials; our dependence on suppliers, collaborative partners and other third parties and the prospects and timing for negotiating supply agreements, corporate collaborations or licensing arrangements; our ability to attract and retain key personnel; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at http:www.sedar.com.
Assumptions underlying our expectations regarding forward-looking statements or information contained in this press release include, among others, that future clinical trial results will be favorable; that our drug candidate will treat target diseases as intended; that we will raise enough capital, on reasonable terms and in a timely manner; that we will retain our key personnel; that we will obtain the necessary regulatory approvals.
In the event that any of these assumptions prove to be incorrect, or in the event that we are impacted by any of the risks identified above, we may not be able to continue in our business as planned.
For a complete discussion of the assumptions, risks and uncertainties related to our business, you are encouraged to review our filings with Canadian securities regulatory authorities, filed on SEDAR at http://www.sedar.com.
All forward-looking statements and information made herein are based on our current expectations as of the date hereof and we disclaim any intention or obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.
Web 2.0 Latest News
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
SYS-CON Featured Whitepapers
Most Read This Week